Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
ABSTRACT The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2022-12-01
|
| Series: | mBio |
| Online Access: | https://journals.asm.org/doi/10.1128/mbio.02653-22 |
| _version_ | 1797979887462514688 |
|---|---|
| author | Michael J. Joyner Nigel Paneth |
| author_facet | Michael J. Joyner Nigel Paneth |
| author_sort | Michael J. Joyner |
| collection | DOAJ |
| description | ABSTRACT The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined. |
| first_indexed | 2024-04-11T05:46:01Z |
| format | Article |
| id | doaj.art-b27d089037f24a9585b89115324cebeb |
| institution | Directory Open Access Journal |
| issn | 2150-7511 |
| language | English |
| last_indexed | 2024-04-11T05:46:01Z |
| publishDate | 2022-12-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | mBio |
| spelling | doaj.art-b27d089037f24a9585b89115324cebeb2022-12-22T04:42:14ZengAmerican Society for MicrobiologymBio2150-75112022-12-0113610.1128/mbio.02653-22Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”Michael J. Joyner0Nigel Paneth1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USADepartment of Epidemiology and Biostatistics, Michigan State University, College of Human Medicine, East Lansing, Michigan, USAABSTRACT The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined.https://journals.asm.org/doi/10.1128/mbio.02653-22 |
| spellingShingle | Michael J. Joyner Nigel Paneth Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” mBio |
| title | Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” |
| title_full | Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” |
| title_fullStr | Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” |
| title_full_unstemmed | Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” |
| title_short | Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” |
| title_sort | commentary on outcomes of convalescent plasma with defined high versus lower neutralizing antibody titers against sars cov 2 among hospitalized patients coronavirus inactivating plasma covip study |
| url | https://journals.asm.org/doi/10.1128/mbio.02653-22 |
| work_keys_str_mv | AT michaeljjoyner commentaryonoutcomesofconvalescentplasmawithdefinedhighversuslowerneutralizingantibodytitersagainstsarscov2amonghospitalizedpatientscoronavirusinactivatingplasmacovipstudy AT nigelpaneth commentaryonoutcomesofconvalescentplasmawithdefinedhighversuslowerneutralizingantibodytitersagainstsarscov2amonghospitalizedpatientscoronavirusinactivatingplasmacovipstudy |